-
C.
Lyu,
Rui
Wang,
Shaolei
Li,
Shi
Yan,
Yu-zhao
Wang,
Jinfeng
Chen,
Liang
Wang,
Yi-nan
Liu,
Zhanlin
Guo,
Jia
Wang,
Y.
Pei,
Lei
Yu,
N.
Wu,
Jun-chen
Chen,
Yanheng
Liu,
Shanqing
Li,
B.
Han,
L.
Ding,
L.
Mao,
Yue
Yang
(2021)
Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.
Journal of Clinical Oncology, 39
-
Sreenath
Sharma,
D.
Bell,
J.
Settleman,
D.
Haber
(2007)
Epidermal growth factor receptor mutations in lung cancer
Nature Reviews Cancer, 7
-
M.
Cohen,
Grant
Williams,
R.
Sridhara,
Gang
Chen,
R.
Pazdur
(2003)
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
The oncologist, 8 4
-
Staging of thoracic malignancies: implications for the reporting pathologist
-
T.
Reungwetwattana,
K.
Nakagawa,
B.
Cho,
M.
Cobo,
E.
Cho,
A.
Bertolini,
S.
Bohnet,
Caicun
Zhou,
K.
Lee,
N.
Nogami,
I.
Okamoto,
N.
Leighl,
R.
Hodge,
A.
McKeown,
Andrew
Brown,
Y.
Rukazenkov,
S.
Ramalingam,
J.
Vansteenkiste
(2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
N.
Guibert,
Yue-Houng
Hu,
N.
Feeney,
Y.
Kuang,
V.
Plagnol,
G.
Jones,
K.
Howarth,
J.
Beeler,
C.
Paweletz,
G.
Oxnard
(2018)
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer
Annals of Oncology, 29
-
M
Majem,
J
Goldman,
T
John
(2021)
OA06.03 patient-reported
outcomes from ADAURA: osimertinib as adjuvant therapy in patients with
resected EGFR mutated (EGFRm) NSCLC
J Thorac
Oncol, 16
-
TAGRISSO® (osimertinib)
-
N
Colclough,
P
Ballard,
P
Barton
(2016)
Preclinical comparison of
the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with
other irreversible next generation EGFR TKIs
Eur J
Cancer, 69
-
Health Canada approves Tagrisso® (osimertinib) as first-line treatment for EGFR-mutated non-small cell lung cancer
-
V.
Papadimitrakopoulou,
Tony
Mok,
J.-Y.
Han,
Myung-Ju
Ahn,
A.
Delmonte,
Suresh
Ramalingam,
S-W.
Kim,
Frances
Shepherd,
Frances
Shepherd,
J.
Laskin,
Y.
He,
Hiroaki
Akamatsu,
W.
Theelen,
W.
Su,
Thomas
John,
Martin
Sebastian,
H.
Mann,
M.
Miranda,
G.
Laus,
Y.
Rukazenkov,
Y.
Wu
(2020)
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Annals of oncology : official journal of the European Society for Medical Oncology
-
N.
Thatcher,
A.
Chang,
P.
Parikh,
J.
Pereira,
T.
Ciuleanu,
J.
Pawel,
S.
Thongprasert,
E.
Tan,
K.
Pemberton,
V.
Archer,
K.
Carroll
(2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
The Lancet, 366
-
M.
Ahluwalia,
K.
Becker,
B.
Levy
(2018)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
The oncologist, 23 10
-
T.
Mok,
Yi-long
Wu,
M.
Ahn,
M.
Garassino,
H.
Kim,
S.
Ramalingam,
F.
Shepherd,
Yong
He,
H.
Akamatsu,
W.
Theelen,
C.
Lee,
M.
Sebastian,
A.
Templeton,
H.
Mann,
M.
Marotti,
S.
Ghiorghiu,
V.
Papadimitrakopoulou
(2017)
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
The New England Journal of Medicine, 376
-
H.
Hansen,
M.
Ro̸rth
(1990)
Lung cancer.
Cancer chemotherapy and biological response modifiers, 11
-
N.
Pennell,
J.
Neal,
J.
Chaft,
C.
Azzoli,
P.
Jänne,
R.
Govindan,
T.
Evans,
D.
Costa,
H.
Wakelee,
R.
Heist,
M.
Shapiro,
A.
Muzikansky,
S.
Murthy,
M.
Lanuti,
V.
Rusch,
M.
Kris,
L.
Sequist
(2019)
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 2
-
P.
Ballard,
J.
Yates,
Zhenfan
Yang,
Dong-Wan
Kim,
J.
Yang,
M.
Cantarini,
K.
Pickup,
Angela
Jordan,
Mike
Hickey,
Matthew
Grist,
Matthew
Box,
P.
Johnström,
K.
Varnäs,
J.
Malmquist,
K.
Thress,
P.
Jänne,
D.
Cross
(2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Clinical Cancer Research, 22
-
(2020)
: results from the ADJUVANT ( CTONG 1104 ) study
-
N.
Hanna,
A.
Robinson,
S.
Temin,
Sherman
Baker,
J.
Brahmer,
P.
Ellis,
L.
Gaspar,
Rami
Haddad,
P.
Hesketh,
D.
Jain,
I.
Jaiyesimi,
David
Johnson,
N.
Leighl,
Pamela
Moffitt,
T.
Phillips,
Gregory
Riely,
R.
Rosell,
J.
Schiller,
B.
Schneider,
Navneet
Singh,
D.
Spigel,
Joan
Tashbar,
G.
Masters
(2021)
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
A.
Gazdar
(2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Oncogene, 28
-
H
Zhang
(2016)
Three generations of epidermal growth factor
receptor tyrosine kinase inhibitors developed to revolutionize the therapy
of lung cancer
Drug Des Devel Ther, 10
-
A.
Gelatti,
A.
Drilon,
F.
Santini
(2019)
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Lung cancer, 137
-
(2019)
Osimertinib
Reactions Weekly, 1784
-
C.
Butts,
K.
Ding,
L.
Seymour,
P.
Twumasi-Ankrah,
B.
Graham,
D.
Gandara,
David
Johnson,
K.
Kesler,
Mark
Green,
M.
Vincent,
Y.
Cormier,
G.
Goss,
B.
Findlay,
M.
Johnston,
M.
Tsao,
F.
Shepherd
(2010)
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 1
-
M.
Nagasaka,
M.
Uddin,
M.
Al-Hallak,
S.
Rahman,
S.
Balasubramanian,
A.
Sukari,
A.
Azmi
(2021)
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer
Molecular Cancer, 20
-
P.
Goldstraw,
K.
Chansky,
J.
Crowley,
R.
Rami-Porta,
H.
Asamura,
W.
Eberhardt,
A.
Nicholson,
P.
Groome,
A.
Mitchell,
V.
Bolejack,
R.
Rami-Porta,
D.
Ball,
D.
Beer,
R.
Beyruti,
F.
Detterbeck,
Wilfried
Eberhardt,
J.
Edwards,
F.
Galateau-Salle,
D.
Giroux,
F.
Gleeson,
James
Huang,
C.
Kennedy,
Jhingook
Kim,
Y.
Kim,
L.
Kingsbury,
H.
Kondo,
M.
Krasnik,
K.
Kubota,
A.
Lerut,
G.
Lyons,
M.
Marino,
E.
Marom,
J.
Meerbeeck,
T.
Nakano,
A.
Nowak,
M.
Peake,
T.
Rice,
K.
Rosenzweig,
E.
Ruffini,
V.
Rusch,
N.
Saijo,
P.
Schil,
J.
Sculier,
L.
Shemanski,
K.
Stratton,
Kenji
Suzuki,
Y.
Tachimori,
C.
Thomas,
W.
Travis,
M.
Tsao,
A.
Turrisi,
J.
Vansteenkiste,
Hirokazu
Watanabe,
Yi‐Long
Wu,
P.
Baas,
J.
Erasmus,
S.
Hasegawa,
K.
Inai,
K.
Kernstine,
H.
Kindler,
L.
Krug,
K.
Nackaerts,
H.
Pass,
D.
Rice,
C.
Falkson,
P.
Filosso,
G.
Giaccone,
K.
Kondo,
M.
Lucchi,
M.
Okumura,
E.
Blackstone,
A.
Cavaco,
A.
Barrera,
Abal
Arca,
Parente
Lamelas,
Arnau
Obrer,
Guijarro
Jorge,
D.
Ball,
G.
Bascom,
B.
Orozco,
González
Castro,
M.
Blum,
D.
Chimondeguy,
V.
Cvijanović,
S.
Defranchi,
B.
Navarro,
Escobar
Campuzano,
Macía
Vidueira,
F.
Araujo,
André
Garcia,
K.
Fong,
Francisco
Corral,
C.
Gonzalez,
Freixinet
Gilart,
García
Arangüena,
García
Barajas,
P.
Girard,
T.
Goksel,
González
Budiño,
González
Casaurrán,
Gullón
Blanco,
Hernández
Hernández,
Hernández
Rodríguez,
Herrero
Collantes,
Iglesias
Heras,
Izquierdo
Elena,
E.
Jakobsen,
S.
Kostas,
León
Atance,
Núñez
Ares,
M.
Liao,
M.
Losanovscky,
G.
Lyons,
R.
Magaroles,
L.
Júlvez,
Mariñán
Gorospe,
B.
McCaughan,
C.
Kennedy,
M.
Íñiguez,
Miravet
Sorribes,
Naranjo
Gozalo,
Álvarez
Arriba,
Núñez
Delgado,
Padilla
Alarcón,
Peñalver
Cuesta,
J.
Park,
H.
Pass,
Pavón
Fernández,
M.
Rosenberg,
E.
Ruffini,
V.
Rusch,
Sánchez
Escuín,
Saura
Vinuesa,
Serra
Mitjans,
T.
Strand,
D.
Subotic,
S.
Swisher,
R.
Terra,
C.
Thomas,
K.
Tournoy,
P.
Schil,
M.
Velasquez,
Y.
Wu,
K.
Yokoi
(2016)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Journal of Thoracic Oncology, 11
-
M.
Tsuboi,
H.
Kato,
K.
Nagai,
R.
Tsuchiya,
H.
Wada,
H.
Tada,
Y.
Ichinose,
M.
Fukuoka,
Haiyi
Jiang
(2005)
Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer
Anti-Cancer Drugs, 16
-
Yi-long
Wu,
M.
Tsuboi,
Jie
He,
T.
John,
C.
Grohé,
M.
Majem,
J.
Goldman,
K.
Laktionov,
Sang-We
Kim,
T.
Kato,
H.
Vu,
Shun
Lu,
K.
Lee,
C.
Akewanlop,
Chong-Jen
Yu,
F.
Marinis,
L.
Bonanno,
M.
Dómine,
F.
Shepherd,
L.
Zeng,
R.
Hodge,
A.
Atasoy,
Y.
Rukazenkov,
R.
Herbst
(2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
The New England journal of medicine
-
F.
Hsu,
A.
Caluwé,
David
Anderson,
A.
Nichol,
T.
Toriumi,
Cheryl
Ho
(2016)
EGFR mutation status on brain metastases from non-small cell lung cancer.
Lung cancer, 96
-
P.
Postmus,
K.
Kerr,
M.
Oudkerk,
S.
Senan,
D.
Waller,
J.
Vansteenkiste,
C.
Escriu,
S.
Peters
(2017)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 28 Suppl 4
-
Lakshmi
Chintala,
R.
Kurzrock
(2010)
Epidermal growth factor receptor mutation and diverse tumors: Case report and concise literature review
Molecular Oncology, 4
-
M
Nagasaka,
MH
Uddin,
MN
Al-Hallak
(2021)
Liquid biopsy for therapy
monitoring in early-stage non-small cell lung cancer
Mol Cancer, 20
-
H.
Wakelee,
N.
Altorki,
Caicun
Zhou,
I.
Vynnychenko,
O.
Goloborodko,
A.
Luft,
A.
Akopov,
-.
Marti,
H.
Kenmotsu,
Yuh-Min
Chen,
A.
Chella,
S.
Sugawara,
Fan
Wu,
Jing
Yi,
Y.
Deng,
M.
McCleland,
E.
Felip
(2021)
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology
-
K.
Vishwanathan,
A.
Varrone,
K.
Varnäs,
A.
Jucaite,
Z.
Cselényi,
P.
Johnström,
M.
Schou,
Ana
Vasquez-Romero,
Mohammed
Moein,
C.
Halldin,
Andrew
Brown,
L.
Farde
(2018)
Abstract CT013: Osimertinib displays high brain exposure in healthy subjects with intact blood-brain barrier: a microdose positron emission tomography (PET) study with11C-labelled osimertinib
Clinical Trials
-
A.
Nicholson,
M.
Tsao,
W.
Travis,
Deepa
Patil,
F.
Galateau-Salle,
M.
Marino,
S.
Dacic,
M.
Beasley,
K.
Butnor,
Y.
Yatabe,
H.
Pass,
V.
Rusch,
F.
Detterbeck,
H.
Asamura,
T.
Rice,
R.
Rami-Porta
(2018)
Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.
Archives of pathology & laboratory medicine, 142 5
-
J.
Pignon,
H.
Tribodet,
G.
Scagliotti,
J.
Douillard,
F.
Shepherd,
R.
Stephens,
A.
Dunant,
V.
Torri,
R.
Rosell,
L.
Seymour,
S.
Spiro,
E.
Rolland,
R.
Fossati,
D.
Aubert,
K.
Ding,
D.
Waller,
T.
Chevalier
(2008)
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
-
T
Le Chevalier
(2010)
Adjuvant chemotherapy for resectable
non-small-cell lung cancer: where is it going?
Ann Oncol, 21
-
P
Postmus,
K
Kerr,
M
Oudkerk
(2017)
Early and locally advanced
non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up
Ann
Oncol, 28
-
S.
Ramalingam,
J.
Vansteenkiste,
D.
Planchard,
B.
Cho,
J.
Gray,
Y.
Ohe,
Caicun
Zhou,
T.
Reungwetwattana,
Ying
Cheng,
B.
Chewaskulyong,
R.
Shah,
M.
Cobo,
K.
Lee,
P.
Cheema,
M.
Tiseo,
T.
John,
Meng-Chih
Lin,
F.
Imamura,
T.
Kurata,
A.
Todd,
R.
Hodge,
M.
Saggese,
Y.
Rukazenkov,
J.
Soria
(2019)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
The New England journal of medicine
-
J.
Cooper
(1997)
Ajcc Cancer Staging Manual
-
U
Malapelle,
B
Ricciuti,
S
Baglivo
(2018)
Osimertinib
Recent Results Cancer Res
-
Yi-long
Wu,
W.
Zhong,
Ke-Neng
Chen,
Chun
Chen,
Fan
Yang,
Xue-Ning
Yang,
C.
Gu,
W.
Mao,
Qun
Wang,
G.
Qiao,
Ying
Cheng,
Lin
Xu,
Changli
Wang,
Mingwei
Chen,
Hong-Hong
Yan,
R.
Liao,
Xuchao
Zhang,
Jin-Ji
Yang,
S.
Liu,
Qing
Zhou
(2021)
CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small cell lung cancer.
Journal of Clinical Oncology, 39
-
N.
Abu-Rustum,
C.
Yashar,
Sarah
Bean,
Kristin
Bradley,
Susan
Campos,
Hye
Chon,
Christina
Chu,
David
Cohn,
M.
Crispens,
Shari
Damast,
Oliver
Dorigo,
P.
Eifel,
Christine
Fisher,
Peter
Frederick,
David
Gaffney,
Ernest
Han,
W.
Huh,
J.
Lurain,
Andrea
Mariani,
David
Mutch,
Christa
Nagel,
Larissa
Nekhlyudov,
A.
Fader,
S.
Remmenga,
R.
Reynolds,
Rachel
Sisodia,
T.
Tillmanns,
Stefanie
Ueda,
E.
Wyse,
Nicole
Mcmillian,
Jillian
Scavone
(2019)
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN, 17 11
-
G.
Goss,
C.
O'Callaghan,
I.
Lorimer,
M.
Tsao,
G.
Masters,
J.
Jett,
M.
Edelman,
R.
Lilenbaum,
H.
Choy,
F.
Khuri,
K.
Pisters,
D.
Gandara,
K.
Kernstine,
C.
Butts,
J.
Noble,
T.
Hensing,
K.
Rowland,
J.
Schiller,
K.
Ding,
F.
Shepherd
(2013)
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 27
-
P.
Cagle,
T.
Allen,
R.
Olsen
(2013)
Lung cancer biomarkers: present status and future developments.
Archives of pathology & laboratory medicine, 137 9
-
H.
Tada,
T.
Mitsudomi,
T.
Yamanaka,
K.
Sugio,
M.
Tsuboi,
I.
Okamoto,
Y.
Iwamoto,
N.
Sakakura,
S.
Sugawara,
S.
Atagi,
Toshiaki
Takahashi,
H.
Hayashi,
M.
Okada,
H.
Yoshioka,
H.
Inokawa,
Kazuhisa
Takahashi,
M.
Higashiyama,
I.
Yoshino,
K.
Nakagawa
(2021)
Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.
Journal of Clinical Oncology, 39
-
W.
Zhong,
Qun
Wang,
W.
Mao,
Songtao
Xu,
Lin
Wu,
Yi
Shen,
Yongyu
Liu,
Chun
Chen,
Ying
Cheng,
Lin
Xu,
Jun
Wang,
K.
Fei,
Xiao-fei
Li,
Jian
Li,
Cheng
Huang,
Zhidong
Liu,
Shun
Xu,
Ke-Neng
Chen,
Shi-dong
Xu,
Lunxu
Liu,
P.
Yu,
Buhai
Wang,
Haining
Ma,
Hong-Hong
Yan,
Xue-Ning
Yang,
Qing
Zhou,
Yi-long
Wu
(2018)
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
The Lancet. Oncology, 19 1
-
T.
Chevalier
(2010)
Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?
Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 7
-
H.
Sung,
J.
Ferlay,
R.
Siegel,
M.
Laversanne,
I.
Soerjomataram,
A.
Jemal,
F.
Bray
(2021)
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
CA: A Cancer Journal for Clinicians, 71
-
Yi-long
Wu,
Ying
Cheng,
Jianying
Zhou,
Shun
Lu,
Yiping
Zhang,
Jun
Zhao,
Dong-Wan
Kim,
R.
Soo,
Sang-We
Kim,
H.
Pan,
Yuh-Min
Chen,
C.
Chian,
Xiaoqing
Liu,
D.
Tan,
R.
Bruns,
J.
Straub,
A.
Johne,
J.
Scheele,
Keunchil
Park,
J.
Yang
(2020)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
The Lancet. Respiratory medicine
-
J.
Zeng,
W.
Mao,
Qixun
Chen,
T.
Luo,
Yi-long
Wu,
Qing
Zhou,
Xue-Ning
Yang,
Hong-Hong
Yan,
W.
Zhong,
Qun
Wang,
Songtao
Xu,
Lin
Wu,
Yicong
Shen,
Yongyu
Liu,
Chun
Chen,
Ying
Cheng,
Lin
Xu,
Jun
Wang,
K.
Fei,
Xiao-fei
Li,
Jian
Li,
Cheng
Huang,
Zhidong
Liu,
Shun-jiang
Xu,
Ke-Neng
Chen,
Shi-dong
Xu,
Lunxu
Liu,
P.
Yu,
Buhai
Wang,
Haining
Ma
(2020)
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
Lung cancer, 150
-
K.
Kelly,
K.
Chansky,
L.
Gaspar,
K.
Albain,
J.
Jett,
Y.
Ung,
D.
Lau,
J.
Crowley,
D.
Gandara
(2008)
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 15
-
Yi-long
Wu,
R.
Herbst,
H.
Mann,
Y.
Rukazenkov,
M.
Marotti,
M.
Tsuboi
(2018)
ADAURA: Phase III, Double‐blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation‐positive Early‐stage NSCLC After Complete Surgical Resection
Clinical Lung Cancer, 19
-
FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations
-
J.
Sands,
S.
Mandrekar,
G.
Oxnard,
D.
Kozono,
S.
Hillman,
S.
Dahlberg,
Zhuoxin
Sun,
J.
Chaft,
R.
Govindan,
D.
Gerber,
J.
Gray,
S.
Malik,
M.
Mooney,
P.
Jänne,
E.
Vokes,
K.
Kelly,
S.
Ramalingam,
T.
Stinchcombe
(2020)
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
Journal of Clinical Oncology, 38
-
TAGRISSO®
(osimertinib)
-
D.
Datta,
B.
Lahiri
(2003)
Preoperative evaluation of patients undergoing lung resection surgery.
Chest, 123 6
-
US FDA approves Tagrisso as
1st-line treatment for EGFR-mutated non-small cell lung
cancer
-
M
Tsuboi,
Y
Wu,
J
He
(2020)
LBA1 Osimertinib adjuvant
therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA):
central nervous system (CNS) disease recurrence
Ann
Oncol, 31
-
M.
Kris,
L.
Gaspar,
J.
Chaft,
E.
Kennedy,
C.
Azzoli,
P.
Ellis,
Steven
Lin,
H.
Pass,
R.
Seth,
F.
Shepherd,
D.
Spigel,
John
Strawn,
Y.
Ung,
M.
Weyant
(2017)
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 25
-
D.
Pfister,
K.
Ang,
D.
Brizel
(2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
-
Wei-Yuan
Chang,
Yi-Lin
Wu,
P.
Su,
S.
Yang,
Chien-Chung
Lin,
W.
Su
(2018)
The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis
PLoS ONE, 13
-
US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer
-
T
Reungwetwattana,
K
Nakagawa,
BC
Cho
(2018)
CNS response to osimertinib
versus standard epidermal growth factor receptor tyrosine kinase inhibitors
in patients with untreated EGFR-mutated advanced non-small-cell lung
cancer
J Clin Oncol, 36
-
EMA
RECOMMENDS EXTENSION OF THERAPEUTIC INDICATIONS FOR
OSIMERTINIB
-
RS
Herbst,
JV
Heymach,
SM
Lippman
(2008)
Lung cancer
N Engl J
Med, 359
-
M.
Majem,
J.
Goldman,
T.
John,
C.
Grohé,
K.
Laktionov,
S.
Kim,
T.
Kato,
H.
Vu,
Shun
Lu,
K.
Lee,
C.
Akewanlop,
C.
Yu,
F.
Marinis,
L.
Bonanno,
M.
Dómine,
F.
Shepherd,
L.
Zeng,
D.
Kulkarni,
N.
Medić,
M.
Tsuboi,
R.
Herbst,
Yi-long
Wu
(2021)
OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC
Journal of Thoracic Oncology, 16
-
N.
Colclough,
P.
Ballard,
P.
Barton,
Kan
Chen,
D.
Cross,
M.
Finlay,
L.
Han,
A.
Janefeldt,
P.
Johnström,
R.
Ward,
G.
Wrigley,
Y.
Yan,
J.
Yates,
D.
Zhang,
Z.
Zhang
(2016)
Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs
European Journal of Cancer, 69
-
Health Canada approves Tagrisso® (osimertinib) as first-line
treatment for EGFR-mutated non-small cell lung cancer
-
Haijun
Zhang
(2016)
Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
Drug Design, Development and Therapy, 10
-
D.
Yue,
Shidong
Xu,
Qun
Wang,
Xiaofei
Li,
Yi
Shen,
Heng
Zhao,
Chun
Chen,
W.
Mao,
Wei
Liu,
Junfeng
Liu,
Lan-Jun
Zhang,
Haitao
Ma,
Qiang
Li,
Yue
Yang,
Yongyu
Liu,
Haiquan
Chen,
Zhenfa
Zhang,
Bin
Zhang,
Fuyu
Gong,
Changli
Wang
(2021)
Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.
Journal of Clinical Oncology, 39
-
J.
Yang,
Sang-We
Kim,
Dong-Wan
Kim,
Jong-Seok
Lee,
B.
Cho,
J.
Ahn,
Dae-Ho
Lee,
T.
Kim,
J.
Goldman,
R.
Natale,
Andrew
Brown,
B.
Collins,
J.
Chmielecki,
K.
Vishwanathan,
A.
Mendoza‐Naranjo,
M.
Ahn
(2019)
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
Journal of Clinical Oncology, 38
-
Yi‐Long
Wu,
W.
Zhong,
Qun
Wang,
W.
Mao,
Songtao
Xu,
Lin
Wu,
Chun
Chen,
Ying
Cheng,
Lin
Xu,
Jun
Wang,
Xiaofei
Li,
Jian
Li,
Cheng
Huang,
Zhidong
Liu,
Shun
Xu,
Jin-Ji
Yang,
Hong-Hong
Yan,
Xue-Ning
Yang,
S.
Liu,
Qing
Zhou
(2020)
CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.
Journal of Clinical Oncology, 38
-
EMA RECOMMENDS EXTENSION OF THERAPEUTIC INDICATIONS FOR OSIMERTINIB
-
FDA approves osimertinib for EGFR
T790M-positive NSCLC
-
Song‐Tao
Xu,
Jun-jie
Xi,
W.
Zhong,
W.
Mao,
Lin
Wu,
Yi
Shen,
Yongyu
Liu,
Chun
Chen,
Ying
Cheng,
Lin
Xu,
Jun
Wang,
Ke
Fei,
Xiao-fei
Li,
Jian
Li,
Cheng
Huang,
Zhidong
Liu,
Shun
Xu,
Ke-Neng
Chen,
Shi-dong
Xu,
Lunxu
Liu,
P.
Yu,
Buhai
Wang,
Haining
Ma,
Hong-Hong
Yan,
Xue-Ning
Yang,
Yongxing
Zhang,
Jiayang
Yin,
Qun
Wang,
Yi-long
Wu
(2019)
The Unique Spatial‐Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Journal of Thoracic Oncology, 14
-
FDA approves osimertinib as adjuvant
therapy for non-small cell lung cancer with EGFR mutations
-
Wenhui
Zhong,
Qun
Wang,
W.
Mao,
Songtao
Xu,
Lin
Wu,
Yu-cheng
Wei,
Yongyu
Liu,
Chun
Chen,
Ying
Cheng,
R.
Yin,
Fan
Yang,
S.
Ren,
Xiao-fei
Li,
Jian
Li,
Cheng
Huang,
Zhidong
Liu,
Shun
Xu,
Ke-Neng
Chen,
Shi-dong
Xu,
Lunxu
Liu,
P.
Yu,
Buhai
Wang,
Haining
Ma,
Jin-Ji
Yang,
Hong-Hong
Yan,
Xue-Ning
Yang,
S.
Liu,
Qing
Zhou,
Yi-long
Wu
(2020)
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Journal of Clinical Oncology, 39
-
M.
Tsuboi,
Y.
Wu,
Jie
He,
T.
John,
C.
Grohé,
M.
Majem,
J.
Goldman,
K.
Laktionov,
S.
Kim,
T.
Kato,
H.
Vu,
C.
Akewanlop,
C.
Yu,
F.
Marinis,
M.
Dómine,
F.
Shepherd,
C.
Yan,
A.
Atasoy,
R.
Herbst
(2020)
LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Annals of Oncology, 31
-
B.
Chan,
B.
Hughes
(2015)
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
Translational lung cancer research, 4 1
-
FDA approves osimertinib for EGFR T790M-positive NSCLC
-
K.
Kelly,
N.
Altorki,
W.
Eberhardt,
M.
O'Brien,
D.
Spigel,
L.
Crinò,
C.
Tsai,
Joo‐Hang
Kim,
E.
Cho,
P.
Hoffman,
S.
Orlov,
P.
Serwatowski,
Jiuzhou
Wang,
M.
Foley,
J.
Horan,
F.
Shepherd
(2015)
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 34